Literature DB >> 28158532

Barth syndrome cardiomyopathy.

Jan Dudek1, Christoph Maack2.   

Abstract

Barth syndrome (BTHS) is an inherited form of cardiomyopathy, caused by a mutation within the gene encoding the mitochondrial transacylase tafazzin. Tafazzin is involved in the biosynthesis of the unique phospholipid cardiolipin (CL), which is almost exclusively found in mitochondrial membranes. CL directly interacts with a number of essential protein complexes in the mitochondrial membranes including the respiratory chain, mitochondrial metabolite carriers, and proteins, involved in shaping mitochondrial morphology. Here we describe, how in BTHS CL deficiency causes changes in the morphology of mitochondria, structural changes in the respiratory chain, decreased respiration, and increased generation of reactive oxygen species. A large number of cellular and animal models for BTHS have been established to elucidate how mitochondrial dysfunction induces sarcomere disorganization and reduced contractility, resulting in dilated cardiomyopathy in vivo.

Entities:  

Year:  2017        PMID: 28158532     DOI: 10.1093/cvr/cvx014

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  25 in total

Review 1.  Report on the Ion Channel Symposium : Organized by the German Cardiac Society Working Group on Cellular Electrophysiology (AG 18).

Authors:  Niels Voigt; Fleur Mason; Dierk Thomas
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-01-08

Review 2.  Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.

Authors:  Hana M Zegallai; Grant M Hatch
Journal:  Mol Cell Biochem       Date:  2021-01-07       Impact factor: 3.396

3.  Targeted overexpression of catalase to mitochondria does not prevent cardioskeletal myopathy in Barth syndrome.

Authors:  Jordan M Johnson; Patrick J Ferrara; Anthony R P Verkerke; Chanel B Coleman; Edward J Wentzler; P Darrell Neufer; Kimberly A Kew; Lisandra E de Castro Brás; Katsuhiko Funai
Journal:  J Mol Cell Cardiol       Date:  2018-07-02       Impact factor: 5.000

Review 4.  The updated view on induced pluripotent stem cells for cardiovascular precision medicine.

Authors:  Yong Wang; Wei Lei; Jingsi Yang; Xuan Ni; Lingqun Ye; Zhenya Shen; Shijun Hu
Journal:  Pflugers Arch       Date:  2021-02-17       Impact factor: 3.657

Review 5.  Role of Cardiolipin in Mitochondrial Signaling Pathways.

Authors:  Jan Dudek
Journal:  Front Cell Dev Biol       Date:  2017-09-29

6.  Loss of Peter Pan (PPAN) Affects Mitochondrial Homeostasis and Autophagic Flux.

Authors:  David P Dannheisig; Eileen Beck; Enrico Calzia; Paul Walther; Christian Behrends; Astrid S Pfister
Journal:  Cells       Date:  2019-08-14       Impact factor: 6.600

7.  Plasmalogen loss caused by remodeling deficiency in mitochondria.

Authors:  Tomohiro Kimura; Atsuko K Kimura; Mindong Ren; Vernon Monteiro; Yang Xu; Bob Berno; Michael Schlame; Richard M Epand
Journal:  Life Sci Alliance       Date:  2019-08-21

8.  Activating transcription factor 3 coordinates differentiation of cardiac and hematopoietic progenitors by regulating glucose metabolism.

Authors:  Hui-Min Yin; Li-Feng Yan; Qian Liu; Zheng Peng; Chi-Yuan Zhang; Yu Xia; Dan Su; Ai-Hua Gu; Yong Zhou
Journal:  Sci Adv       Date:  2020-05-06       Impact factor: 14.136

9.  Late diagnosis of Barth syndrome in a 39-year-old patient with non-compaction cardiomyopathy and neutropenia.

Authors:  Andreas Seitz; Annely Hinck; Raffi Bekeredjian; Udo Sechtem
Journal:  ESC Heart Fail       Date:  2020-01-22

Review 10.  Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies.

Authors:  Quynh Nguyen; Kenji Rowel Q Lim; Toshifumi Yokota
Journal:  Int J Mol Sci       Date:  2020-01-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.